Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2318]

Azacitidine plus nivolumab in older adults with AML or MDS

Prof Annette Hay - Queen's University, Ontario, Canada

Azacitidine plus nivolumab in older adults with AML or MDS ( Prof Annette Hay - Queen's University, Ontario, Canada )

Venetoclax chemo combo active and well-tolerated in children with r/r AML

Dr Seth Karol - St. Jude Children’s Research Hospital, Memphis, USA

Venetoclax chemo combo active and well-tolerated in children with r/r AML ( Dr Seth Karol - St. Jude Children’s Research Hospital, Memphis, USA )

CARTITIUDE-1: BCMA-targeted CAR T-cell therapy shows high response rates in...

Prof Deepu Madduri - Mount Sinai, New York, USA

CARTITIUDE-1: BCMA-targeted CAR T-cell therapy shows high response rates in patients with multiple myeloma ( Prof Deepu Madduri - Mount Sinai, New York, USA )

CANDOR: Triple drug combo delays disease progression in stubborn multiple...

Dr Saad Usmani - Levine Cancer Institute, Charlotte, USA

CANDOR: Triple drug combo delays disease progression in stubborn multiple myeloma ( Dr Saad Usmani - Levine Cancer Institute, Charlotte, USA )

Daratumuab, carfilzomib and dexamethasone increases survival in patients with...

Dr Saad Usmani - Levine Cancer Institute, Charlotte, USA

$Daratumuab, carfilzomib and dexamethasone increases survival in patients with relapsed/refractory multiple myeloma ( Dr Saad Usmani - Levine Cancer Institute, Charlotte, USA )$

Multiple myeloma highlights from ASH 2019

Prof Heinz Ludwig - Wilhelmeninen Cancer Research Institute, Vienna, Austria

Multiple myeloma highlights from ASH 2019 ( Prof Heinz Ludwig - Wilhelmeninen Cancer Research Institute, Vienna, Austria )

Glasdegib in combination with azacitidine in patients with untreated higher...

Dr Mikkael Sekeres - Cleveland Clinic, Cleveland, USA

Glasdegib in combination with azacitidine in patients with untreated higher-risk myelodysplastic syndromes and AML ( Dr Mikkael Sekeres - Cleveland Clinic, Cleveland, USA )

Addressing the treatment gap for patients with relapsed/refractory primary...

Prof Evangelos Terpos and Prof Efstathios Kastritis

$Addressing the treatment gap for patients with relapsed/refractory primary systemic AL amyloidosis: TOURMALINE-AL1 trial results ( Prof Evangelos Terpos and Prof Efstathios Kastritis )$

Challenges and importance of long-term treatment for newly diagnosed multiple...

Prof Sagar Lonial, Prof Meral Beksaç, Dr Robert Rifkin

Challenges and importance of long-term treatment for newly diagnosed multiple myeloma patients; community-based trial data ( Prof Sagar Lonial, Prof Meral Beksaç, Dr Robert Rifkin )

Evaluating emerging mutations in patients with acute myeloid leukaemia who...

Dr Catherine Smith - University of California San Francisco, San Francisco, USA

Evaluating emerging mutations in patients with acute myeloid leukaemia who relapsed while receiving gilteritinib therapy in the ADMIRAL trial ( Dr Catherine Smith - University of California San Francisco, San Francisco, USA )

Bispecific CAR T-cell therapy as treatment for hard to treat multiple myeloma

Dr Yu Hu - Huazhong University of Science and Technology, Wuhan, China

Bispecific CAR T-cell therapy as treatment for hard to treat multiple myeloma ( Dr Yu Hu - Huazhong University of Science and Technology, Wuhan, China )

CAR T-cell therapy in hard-to-treat multiple myeloma produces sustained...

Dr Yu Hu - Huazhong University of Science and Technology, Wuhan, China

CAR T-cell therapy in hard-to-treat multiple myeloma produces sustained remissions ( Dr Yu Hu - Huazhong University of Science and Technology, Wuhan, China )

More from ecancer